02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
20:45 , Jul 11, 2019 |  BC Extra  |  Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
23:26 , Jun 20, 2019 |  BC Extra  |  Financial News

New listings push IPO pace ahead of last year’s

A spate of biotech IPOs this week in which five companies raised nearly $620 million helped push the biopharma sector’s total haul from NASDAQ listings ahead of 2018’s record pace. Of the five to price...
22:47 , Jun 10, 2019 |  BC Extra  |  Financial News

June 10 Financial Quick Takes: Vivo raises $1.3B for ninth fund; plus Prevail, Dermavant, Akero set terms for IPOs

Vivo has at least $1.3B for next fund  Vivo Capital has raised $1.3 billion toward its ninth fund from 36 investors, according to an SEC filing . The healthcare investment firm did not disclose in...
23:34 , Jun 7, 2019 |  BC Extra  |  Financial News

Stoke, Personalis set terms for NASDAQ IPOs

Stoke and Personalis set similar ranges for their NASDAQ IPOs Friday, which could raise a combined total of $200 million. Genetic diseases company Stoke Therapeutics Inc. (Bedford, Mass.) and cancer genomics company Personalis Inc. (Menlo...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
02:41 , Mar 15, 2019 |  BC Innovations  |  Product Development

Fresh AIMMs for elite responders

AIMM Therapeutics B.V.’s elite responder platform has identified mAbs that distinguish tumor and healthy cells based on protein modifications. The company is one of a handful of players mining the immune systems of cancer patients...
23:56 , Feb 25, 2019 |  BC Extra  |  Company News

Management tracks: Viriom, Matinas, Atreca

Viriom Inc. (San Diego, Calif.) hired Iain Dukes as CEO, a new position at the antiviral company. He is a venture partner at OrbiMed Advisors and serves as chairman of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) as...
23:48 , Sep 14, 2018 |  BioCentury  |  Finance

Solidifying Atreca’s repertoire

Atreca Inc. parlayed preclinical proof-of-concept data from its antibody platform into a $125 million series C round, which will enable the cancer immunotherapy company to bring its two lead programs into the clinic. An undisclosed,...
19:16 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Atreca’s $125M round paves way for first immunotherapy into clinic

Atreca Inc. (Redwood City, Calif.) raised $125 million in a series C round led by an undisclosed U.S.-based healthcare fund, clearing the way for the company to move its first cancer immunotherapy into the clinic....